Pentoxifylline

Generic Name: Pentoxifylline

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈N_₄O_₃

CAS Number: 6493-05-6

Unique Ingredient Identifier: SD6QCT3TSU

Background: Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties. Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated...

Indication: Pentoxifylline is indicated for the treatment of intermittent claudication in patients with chronic occlusive arterial disease. Pentoxifylline may improve limb function and reduce symptoms but cannot replace other therapies such as surgical bypass or removal of vascular obstructions.

Associated Conditions: Intermittent Claudication, Venous Leg Ulcer (VLU), Severe alcoholic liver disease

Associated Therapies: -

Clinical Trials

Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis

Phase 3

Terminated

Conditions: Glomerulonephritis

Interventions: Drug: corticosteroids
Drug: pentoxifylline

First Posted Date: 2006-07-20

Last Posted Date: 2012-11-14

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 7

Registration Number: NCT00354198

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients

Phase 3

Completed

Conditions: Kidney Failure, Chronic

Interventions: Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2006-02-01

Last Posted Date: 2011-07-29

Lead Sponsor: Walter Reed Army Medical Center

Target Recruit Count: 39

Registration Number: NCT00285298

Pentoxifylline in the Treatment of NEC in Premature Neonates

Phase 2

Conditions: Necrotizing Enterocolitis

Interventions: Drug: Pentoxifylline

First Posted Date: 2005-12-30

Last Posted Date: 2008-05-23

Lead Sponsor: Shaare Zedek Medical Center

Target Recruit Count: 50

Registration Number: NCT00271336

Locations: 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel

Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis
Liver Diseases

Interventions: Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2005-12-21

Last Posted Date: 2014-09-09

Lead Sponsor: Northwestern University

Target Recruit Count: 26

Registration Number: NCT00267670

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy

Phase 1

Completed

Conditions: Muscular Dystrophy, Duchenne

Interventions: Drug: Pentoxifylline

First Posted Date: 2005-10-25

Last Posted Date: 2011-10-27

Lead Sponsor: Cooperative International Neuromuscular Research Group

Target Recruit Count: 64

Registration Number: NCT00243789

Locations: 🇮🇱
Hadassah Hospital, Mt. Scopus, Jerusalem, Israel
🇺🇸
University of Tennessee, Memphis, Tennessee, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 8 locations

Pentoxifylline for Acute Alcoholic Hepatitis (AAH)

Phase 1

Terminated

Conditions: Hepatitis, Alcoholic

Interventions: Drug: pentoxifylline

First Posted Date: 2005-09-20

Last Posted Date: 2014-05-13

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 4

Registration Number: NCT00205049

The Use of Pentoxifylline and Vitamin E in the Treatment of Late Radiation Related Injuries

Phase 2

Terminated

Conditions: Wounds and Injuries

First Posted Date: 2005-09-16

Last Posted Date: 2010-08-13

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 50

Registration Number: NCT00188552

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

The Use of Pentoxifylline and Vitamin E in the Treatment of Chronic Breast Pain

Phase 2

Terminated

Conditions: Breast Neoplasms

First Posted Date: 2005-09-16

Last Posted Date: 2010-08-11

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 48

Registration Number: NCT00188669

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Clinical Trial of Pentoxifylline in Patient With Cirrhosis

Phase 3

Completed

Conditions: Cirrhosis
Liver Failure

Interventions: Drug: pentoxifylline
Drug: PLACEBO

First Posted Date: 2005-09-13

Last Posted Date: 2008-01-17

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 342

Registration Number: NCT00162552

Locations: 🇫🇷
Hôpital Beaujon, Clichy, France

Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis

Not Applicable

Completed

Conditions: Primary Glomerulonephritis

First Posted Date: 2005-09-12

Last Posted Date: 2005-09-12

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 20

Registration Number: NCT00154661

Locations: 🇨🇳
Yung-Ming Chen, Taipei, Taiwan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy